Dr. Charles G. Drake is the director of genitourinary oncology, the co-director of the Cancer Immunotherapy Program, and the associate director for clinical research at NewYork-Presbyterian / Columbia University Medical Center.
Dr. Drake’s areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder, and testes. He’s shown how targeting the immune checkpoint LAG-3 can improve the effectiveness of anti-cancer immune responses, and that it works well in combination with anti-PD-1 immunotherapy. He also continues to explore how we can improve the ability of anti-cancer T cells to eliminate tumors.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Drake serves on the CLIP Grant Review Committee.
Immunotherapy represents a new frontier in prostate cancer. We’re also looking at how it can be used synergistically with traditional therapies, both in prostate cancer as well as in other tumor types.
Let's spread the word about Immunotherapy! Click to share this page with your community.